Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic

Related Experiment Video

Updated: Mar 17, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.7K

Janina Kitow1, Anselm A Derda1, Julia Beermann1

  • 1Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany;

American Journal of Physiology. Heart and Circulatory Physiology
|July 17, 2016
PubMed

Insights

Specific long noncoding RNAs (lncRNAs) were found to be elevated in patients with hypertrophic obstructive cardiomyopathy (HOCM). These lncRNAs, uc004cov.4 and uc022bqu.1, show promise as potential biomarkers for identifying HOCM.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart condition with risks of sudden cardiac death.
  • Hypertrophic obstructive cardiomyopathy (HOCM) presents with a left ventricular outflow gradient, distinct symptoms, and treatment needs compared to hypertrophic nonobstructive cardiomyopathy (HNCM).
  • Long noncoding RNAs (lncRNAs) are implicated in mitochondrial and cardiac remodeling processes.

Purpose of the Study:

  • To investigate the expression of mitochondrial and cardiac remodeling-associated lncRNAs in the blood of HOCM and HNCM patients.
  • To determine if specific lncRNAs can differentiate between HOCM and HNCM.
  • To explore the potential of lncRNAs as clinical biomarkers for HOCM.

Main Methods:

  • Serum samples were collected from 57 HOCM patients, 28 HNCM patients, and 26 controls.
  • Expression levels of known mitochondrial and cardiac remodeling-associated lncRNAs were quantified.
  • Receiver operator characteristic (ROC) curve analysis was used to assess diagnostic potential.

Main Results:

  • The lncRNAs uc004cov.4 and uc022bqu.1 were significantly upregulated in HOCM patients compared to controls and HNCM patients.
  • ROC curve analysis demonstrated that uc004cov.4 and uc022bqu.1 could effectively identify HOCM patients.
  • No significant changes in these lncRNAs were observed in HNCM patients.

Conclusions:

  • Specific mitochondrial lncRNAs, uc004cov.4 and uc022bqu.1, are upregulated in HOCM.
  • These lncRNAs serve as reliable indicators for identifying HOCM.
  • uc004cov.4 and uc022bqu.1 have potential for development as future clinical biomarkers for HOCM.

Keywords:
biomarkercardiac remodelingdiagnosishypertrophic cardiomyopathylncRNA

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.3K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
627
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
710
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
732